PIK3CA Mutation (DBCOND0145716)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05216432	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer	Fulvestrant Palbociclib RLY-2608 Ribociclib	treatment	1	recruiting
NCT05759949	First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors	Abemaciclib Fulvestrant Palbociclib Ribociclib	treatment	1	active_not_recruiting
NCT05300048	Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations	Paclitaxel Serabelisib	treatment	1	active_not_recruiting
NCT05472220	Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma	Alpelisib Carboplatin	treatment	1	withdrawn